chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Left arm pain injestion location after still  4 months and numbness in arm and hand.; Left arm pain injestion location after still  4 months and numbness in arm and hand.; Left arm pain injestion location after still  4 months and numbness in arm and hand.; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 59-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 28Jan2022 at 09:15 as dose 3 (booster), single (Lot number: FL3209) at the age of 59 years, in left arm for covid-19 immunisation. The patient's relevant medical history was not reported. The patient took concomitant medications. Past drug history included: Codine, reaction(s): "known allergies: Codine", notes: known allergies: Codine. Vaccination history included: BNT162b2 (Dose Number: 2, Batch/Lot No: ER8727, Location of injection: Arm Left, Vaccine Administration Time: 07:30 AM), administration date: 25Mar2021, when the patient was 58-year-old, for COVID-19 immunization; BNT162b2 (Dose Number: 1, Batch/Lot No: EN6202, Location of injection: Arm Left, Vaccine Administration Time: 07:30 AM), administration date: 04Mar2021, when the patient was 58-year-old, for COVID-19 immunization.  The following information was reported: VACCINATION SITE PAIN (non-serious), HYPOAESTHESIA (non-serious), HYPOAESTHESIA (non-serious) all with onset 28Jan2022 at 10:00, outcome "not recovered" and all described as "Left arm pain injestion location after still  4 months and numbness in arm and hand.". Therapeutic measures were not taken as a result of vaccination site pain, hypoaesthesia, hypoaesthesia.  Additional Information: The patient received no other vaccines within 4 weeks prior to the COVID vaccine. Any other medications the patient received within 2 weeks of vaccination was Multi-vitamin. Prior to vaccination, the patient was not  diagnosed with COVID-19. Since the vaccination, the patient has not been tested for COVID-19  No follow-up attempts are possible. No further information is expected.
Tingling in extremity after 10 minutes of administering vaccine.  Jaw tightness, dizziness, nausea and chills for two days.  Occasional low grad fever for two days.  Fatigue for 5 days.
Headache sore arm, chills, h/a, fatigue, dizzy Narrative:  Other Relevant History:
Patient was given ZOSTAVAX on 12/20/07 and then developed a rash on 12/30.  Presented 1/15/08 for evaluation and was diagnosed with shingles.  Symptoms: 1. shingles.  Treatment Drugs Used: 1 - acyclovir Dose: small amount Units: Freq: Other Route: TOP, 2 - acyclovir Dose: 800 Units: MG Freq: Other Route: PO, 3 - gabapentin Dose: 800 Units: MG Freq: EVERYDAY Route: PO
40 minutes after receiving dose one of Moderna Covid19 vaccine, patient reported feeling hot, tingly, and "a weight on chest", but no trouble breathing. Symptoms were worse on effort, and improved some upon rest. Upon inspection, injection site was red and warm. Patient was monitored for 1 hour, until 11:30 when they reported feeling okay to go back to work. Upon, follow-up at 1:30 AM and in the morning at 10 AM, patient reported feeling much better
Within 2 hours, large egg-sized lump, hot to touch. Daily temperature (fever) for twelve days from 9/10 of a degree above normal (114 12 days) to 3 degrees above. Headache 14 days. General Malaise.
Fine raised red rash over her body; throat swelling; diarrhea; high pitched cough productive with clear thin secretions; This is a spontaneous report from a contactable nurse (patient herself). A 59-year-old female patient received her first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, lot number: EK5730), via an unspecified route of administration on left arm from at 12:30 PM on 23Dec2020 at single dose for COVID-19 immunization. Medical history included depression. Concomitant medication included bupropion hydrochloride (WELLBUTRIN), triazolam (HALCION), fluoxetine hydrochloride (PROZAC), paracetamol (TYLENOL). The patient previously took Lamictal and experienced rash, codeine and experienced hallucination, lamictal for drug allergy, codeine and experienced drug allergy. On 24Dec2020 mid-day (11:00 AM), the patient developed the following S/S (signs and symptoms, which were similar to a Lamictal rash): Fine raised red rash over her body, but significantly heavier to face, neck and lower legs; throat swelling with a high pitched cough (with no difficulty breathing) productive with clear thin secretions; diarrhea. The patient took 6 Benadryl every 4-6 hours, Pepcid twice daily, and had an epi pen available (but did not need it). The cough and rash resolved by late Sunday evening (27Dec2020). The patient did not report to ED because she felt the symptoms were manageable at home. All events reported as non-serious. The outcome of events red rash and cough were recovered on 27Dec2020, the outcome of rest events was unknown. Prior to vaccination, the patient was not diagnosed with COVID-19; Since the vaccination, the patient had not been tested for COVID-19.
I was diagnosed with acute appendicitis /it did not rupture but it was puss filled; This is a spontaneous report from a contactable consumer patient. A 30-year-old female patient (age at vaccination: 29-years-old) received the first dose of BNT162B2 (Pfizer-BIONTECH COVID-19 Vaccine), via an unspecified route of administration in the left arm on 26Mar2021 at 13:00 (Batch/Lot Number: PAA165969) as a single dose for COVID-19 immunization. The patient's medical history was not reported. The patient was not pregnant, had no other vaccines in four weeks, and did not have COVID prior to vaccination. Concomitant medication included birth control (unspecified; reported as other medication in two weeks). Four days after the patient's vaccine, on 30Mar2021, she was diagnosed with acute appendicitis and had to have it removed. She was told that it did not rupture but it was pus filled. The event resulted in a doctor or other healthcare professional office/clinic visit, Emergency room/department or urgent care, and hospitalization (for 2 days). The patient underwent lab tests and procedures which included SARS-CoV-2 test (via nasal swab): negative on 30Mar2021. As treatment, the patient's appendix was removed. Outcome of the event was recovering.
ADULT OBSTRUCTIVE SLEEP APNEA, SEVERE CHRONIC HYPOXEMIC RESPIRATORY FAILURE 1/24/2023  --  RECURRENCE OF HOSPITALIZATION WITH SAME SYMPTOMS
12 hrs after vaccinated: loss of taste/smell 4/19-26: fatigue 4/26-5/9: shortness of breath during night.. restless sleep 5/10-13: periodic shortness of breath throughout day 5/13-20: admitted to hospital - pulmonary embolism & congestive heart failure IV treatment: heparin 5 days  Several medications each day/night taken
Redness, swelling, warmth, induration, 10cm surrounding injection site beginning 28 hrs after injection
4 hrs-post vaccination-severe allergic reaction-massive hives, rampaging heart, chest pain, trouble breathing. Call Dr, took Benadryl, friend attended. All subsided after 3 days. Not allergic to eggs.
Pain at injection site, fever (102), aches, chills, muscle pain, headache, dry cough.  No treatment was sought; symptoms were significant for 36 hours beginning about 6 hours after injection, then began to subside.  Symptoms gone after 48 hours
vomiting; sweats; Joint pain; chills; Severe Muscle Aches; nausea; lingering fatigue; headache; This spontaneous report received from a patient concerned a female of unspecified age. The patient's weight, height, and medical history were not reported.The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: Unknown) dose was not reported, 1 total, administered on 12-MAR-2021 18:45 for prophylactic vaccination. Batch number was not reported and has been requested. No concomitant medications were reported. On 13-MAR-2021 04:00, the subject experienced vomiting. On 13-MAR-2021 04:00, the subject experienced sweats. On 13-MAR-2021 04:00, the subject experienced joint pain. On 13-MAR-2021 04:00, the subject experienced chills. On 13-MAR-2021 04:00, the subject experienced severe muscle aches. On 13-MAR-2021 04:00, the subject experienced nausea. On 13-MAR-2021 04:00, the subject experienced lingering fatigue. On 13-MAR-2021 04:00, the subject experienced headache. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from vomiting, sweats, joint pain, chills, severe muscle aches, and nausea on MAR-2021, and was recovering from lingering fatigue, and headache. This report was non-serious.
Patient received Pfizer vaccination #1 approx. 12 noon, and immediately became nauseous.  After several minutes of throwing up in the wastebasket, he became dizzy and clammy and parents helped him to the floor.  Pharmacist gave him 2x12.5mg diphenhydramine chewable for possible allergic rxn happening.  After several more minutes, parents escorted him to their vehicle.  I told mom to give more diphenhydramine after 4 hrs if needed.  Also told her to give Tylenol and have him take it easy the rest of the day.  Told her to call 911 if any breathing difficulty. Also told mom to check with sons doctor before getting second shot.
pain fever exhaustion joint/muscle aches headaches nausea and vomiting mental confusion rash (red, swollen, itchy) started at injection and spread to from shoulder to elbow night sweats all symptoms worsened with movement
can not move my shoulder; This non-serious case was reported by a consumer via interactive digital media and described the occurrence of mobility decreased in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   In OCT-2022, the patient received Shingles vaccine. On an unknown date, an unknown time after receiving Shingles vaccine, the patient experienced mobility decreased (Verbatim: can not move my shoulder). The outcome of the mobility decreased was not resolved.   It was unknown if the reporter considered the mobility decreased to be related to Shingles vaccine.  It was unknown if the company considered the mobility decreased to be related to Shingles vaccine.   Additional Information: GSK Receipt Date: 09-JUL-2023 This case was reported by a patient via interactive digital media. The patient was given the shingles vaccine and he/she still could not move his/her shoulder properly.
This spontaneous case was reported by a pharmacist and describes the occurrence of VACCINATION COMPLICATION (booster side effects), CHILLS (Chill), HEADACHE (Headache) and PYREXIA (light fever) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. No Medical History information was reported. On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced VACCINATION COMPLICATION (booster side effects), CHILLS (Chill), HEADACHE (Headache) and PYREXIA (light fever). At the time of the report, VACCINATION COMPLICATION (booster side effects), CHILLS (Chill), HEADACHE (Headache) and PYREXIA (light fever) outcome was unknown. DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Heart rate: elevated (High) elevated HR 65 (normally 52). The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown. For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments. No Concomitant medication provided. No treatment medication provided.
The site where patient had received shot felt like a mosquito had bit, very itchy.; Small spot red and raised; Small spot red and raised; This is a spontaneous report from a contactable consumer, the patient. A 64-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6204) via an unspecified route of administration in the left arm on 20Mar2021 (at the age of 64-years-old), as a single dose for COVID-19 immunisation. Medical history included eosinophilic esophagitis. It was unknown if the patient had allergies to medications, food, or other products. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EM9809) via an unspecified route of administration in the left arm on 26Feb2021 (at the age of 64-years-old), as a single dose for COVID-19 immunisation. Concomitant medications included Over The Counter (OTC) multi vitamin, taken from an unknown date for an unknown indication. The patient did not receive any other vaccination within four weeks prior to the COVID-19 vaccine. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 02Apr2021, 13 days after the second vaccination, the patient experienced that the site where she had received the shot felt like a mosquito had bit her, very itchy, small spot about the size of the eraser end of a pencil, red and raised, which lasted about two hours and then faded away. The event neither resulted in doctor or other healthcare professional office/clinic visit nor emergency room/department or urgent care. The clinical outcome of the event, site where she had received the shot felt like a mosquito had bit her, very itchy, small spot about the size of the eraser end of a pencil, red and raised was resolved on 02Apr2021.  No follow-up attempts are needed. No further information is expected.
Gout flare; This non-serious case was reported by a consumer and described the occurrence of gout flare in a 69-year-old female patient who received RSVPreF3 adjuvanted (Arexvy) (batch number A4945) for prophylaxis.   Concomitant products included losartan potassium.   On 19-OCT-2023, the patient received Arexvy 1 ml. On 21-OCT-2023, 2 days after receiving Arexvy, the patient experienced gout flare (Verbatim: Gout flare). The outcome of the gout flare was not resolved.   It was unknown if the reporter considered the gout flare to be related to Arexvy.     It was unknown if the company considered the gout flare to be related to Arexvy.   Additional Information: GSK Receipt Date: 24-OCT-2023 It was reported that patient suffered from gout flare after receiving Arexvy vaccination. The reporter consented to follow up via mail.
mom called 1AUG95 stating pt was taken to MD p/hrs of high pitched uncontrollable crying was told related to pertussis called MD again on 3AUG95 & stated pt still had t100; told to cont giving APAP;
This spontaneous report as received from a medical assistant refers to a 16 year old patient of unknown gender. The patient's drug allergies and pertinent medical history was not reported. On 09-JUL-2014 the patient was vaccinated with first dose of GARDASIL (dose, frequency and route of administration were not reported) (lot # K005083, expiry date: 04-NOV-2016) and second dose of VAQTA (dose, frequency and route of administration were not reported) (lot # J014584, expiry date; 16-JAN-2016) which were stored improperly. No adverse effects were noted. No product quality complaint was reported for GARDASIL and VAQTA. This case is linked to 1407USA010956, 1407USA012902, 1407USA012903, 1407USA012904, 1407USA012905, 1407USA012906, 1407USA012907, 1407USA012908, 1407USA012909, 1407USA012910, 1407USA012911, 1407USA012912, 1407USA012913, 1407USA012914, 1407USA012915, 1407USA012916, 1407USA012917, 1407USA012919, 1407USA012920, 1407USA012921, 1407USA012922, 1407USA012923, 1407USA012924, 1407USA012925, 1407USA012926, 1407USA012927, 1407USA012928, 1407USA012929, 1407USA012930, 1407USA012931, 1407USA012932, 1407USA012933, 1407USA012934, 1407USA012935, 1407USA012936, 1407USA012937, 1407USA012938, 1407USA012939, 1407USA012940, 1407USA012941, 1407USA012942, 1407USA012943, 1407USA012944, 1407USA012945, 1407USA012946, 1407USA012947, 1407USA012948, 1407USA012949, 1407USA012950, 1407USA012951, 1407USA012952, 1407USA012953, 1407USA012954, 1407USA012955, 1407USA012956, 1407USA012957, 1407USA012958, 1407USA012959, 1407USA012960, 1407USA012961, 1407USA012962, 1407USA012963, 1407USA012964, 1407USA012965, 1407USA012966, 1407USA012967, 1407USA012968, 1407USA012969, 1407USA012970, 1407USA012971, 1407USA012972, 1407USA012973, 1407USA012974, 1407USA012975, 1407USA012976, 1407USA012977, 1407USA012978, 1407USA012979, 1407USA012980, 1407USA012981, 1407USA012982, 1407USA012983, 1407USA012984, 1407USA012985, 1407USA012986, 1407USA012987, 1407USA012988, 1407USA012989, 1407USA012990, 1407USA012991, 1407USA012992, 1407USA012993, 1407USA012994, 1407USA012995, 1407USA012996, 1407USA012997, 1407USA012998, 1407USA012999, 1407USA013000, 1407USA013013 and 1407USA013014 (same reporter link). Additional information has been requested.
No adverse effects reported; patient was mistakenly administered one dose of VARIVAX; This spontaneous report was received from a Licensed Practical Nurse referring to a patient of unknown age and gender. The patient's pertinent medical history, concurrent conditions, drug reactions/allergies and concomitant medications were not provided.    On 11-JUN-2019, the patient was mistakenly administered one dose of varicella virus vaccine live (oka/merck) (VARIVAX) by subcutaneous route, lot # R027995, expiry date on 01-OCT-2020, for prophylaxis. No adverse effects were reported.
Systemic: Dizziness / Lightheadness-Medium, Systemic: Fainting / Unresponsive-Medium, Additional Details: pt was dizzy and light headed after vaccine and lost conciousness for a couple of seconds. she was sweaty and a little confused for a couple of seconds. she ate and drank something after and was feeling better and we phoned 911 to check her out. she was released and doing much better.
Vaccines Tdap, MENACTRA, HEP A administered at 11:00 am, 5 min prior to reaction. Symptoms include syncope with LOC <5 seconds, pale, hands/feet tingling. Pt with noted (+) mensus, increased anxiety, increased hunger prior to shots vs as follows- BP-110/76, O2 98%, RA, pulse 68, Resp 20. Pt asked to lie supine with legs elevated, gave sugar beverage. MD at BS.
Headache, dizziness, chest tightness, scratchy throat; No treatments provided in clinic. Patient monitored until EMS arrived. Patient care handed over to EMS.
Initially was a rash on right upper inner thigh, topical steroid prescribed. 2 weeks later was spread to legs and arms, saw dermatologist different steroid applied, rash became more red and itchy. Returned to PCP and was sent out for biopsy. Diagnosed as Gianotti-Crosti disease. No acute illness before vaccination, one possible cold after vaccine was administered, but after rash had started. 4 weeks after rash started was suggested to try a homeopathic remedy. Tried sulphur 30c with no change, recommended to switch to Rhus tox 6c. Started on Friday 10/13 by saturday 10/14 rash had begun to clear, crusting began, no further spread .
Pt was dizzy after getting the injection of Gardasil and fell and needed sutures.
This spontaneous report as received from a medical assistant, referring to a unspecified number of patients of unknown genders and ages. No information regarding the patient's medical history, concurrent conditions or concomitant therapies was provided. On an unknown date, the patients were vaccinated with improperly stored second dose of PROQUAD Lot number M009746, expiration date 23-AUG-2017 (strength and route were not reported) for prophylaxis, however no adverse effects reported. It was reported that the vaccines were exposed to temperature of >-10 C but <8 Centigrade range for a time frame of 1 hour and 4 minutes. The temperature excursion was recorded by a data logger and no previous excursions were reported for the vaccines. There was no product quality complaint involved. This is one of the several reports received from the same reporter. Additional information has been requested.; Sender's Comments: US-009507513-1703USA008048: US-009507513-1703USA008046: US-009507513-1703USA008051: US-009507513-1703USA008050: US-009507513-1703USA008049: US-009507513-1703USA008047: US-009507513-1703USA008052:
She is feeling like she is getting a cold; Feel like I am getting a cold; This is a spontaneous report received from a non-contactable reporter(s) (Consumer or other non HCP) for a Pfizer sponsored program. The reporter is the patient.  A female patient received bnt162b2 (BNT162B2) (Batch/Lot number: unknown) as dose 1, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: NASOPHARYNGITIS (non-serious), outcome "unknown", described as "She is feeling like she is getting a cold; Feel like I am getting a cold".  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Pt recv vax on 2/25/99; on 2/26/99 pt exp swollen/ red/ warm lt leg, fever x 1 day(103-104F); dx=Cefzil
Cellulitis vs. allergic reaction at site of injection starting day after given - erythema, warmth, mild tenderness.
Extreme periods of fatigue starting early evening of Day 1. Continued into Day 2, then increasing localized pain around injection site ( from none, initially) and flu- like ache in lower back. Evening of Day 2 noticed red " welts" and inflammation about 3-4 inches across at injection site. Some swelling, but intense burning/itching. During the night felt like left arm to fingers was numb/ tingling. Day 3 this is persisting.
Pt. stated he had vaccine on May 20. On May 21st - pt. c/o dizziness, joints aching, T. 102, SOB, "heart racing". Took 2 acetaminophen, stayed in bed x 2 days. Then symptoms better by May 23, 2009.
Pt had hives over entire body- MD order two types of creams et oral rx to be given to child;
Pt. received PNEUMOVAX 23 on left deltoid 8/31 as part of routine preventive care. On 9/2 she presented c/o left arm swelling since 8/31, redness and pain that had improved from the day before. She was prescribed Ibuprofen 800 mg every 8 hrs and cool compress.
Issues with Speech; Issues with vision; Issues with ability to stand; shakes; hives; had an allergic reaction; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP) for a Pfizer sponsored program.  A 49 year-old female patient received bnt162b2 (BNT162B2), administration date 02Apr2021 (Batch/Lot number: unknown) at the age of 48 years as dose number unknown, single for covid-19 immunisation. The patient's relevant medical history was not reported. There were no concomitant medications. The following information was reported: HYPERSENSITIVITY (medically significant) with onset 02Apr2021, outcome "recovered" (2021), described as "had an allergic reaction"; SPEECH DISORDER (medically significant), outcome "unknown", described as "Issues with Speech"; VISUAL IMPAIRMENT (medically significant), outcome "unknown", described as "Issues with vision"; DYSSTASIA (medically significant), outcome "unknown", described as "Issues with ability to stand"; TREMOR (medically significant), outcome "unknown", described as "shakes"; URTICARIA (non-serious), outcome "unknown", described as "hives". The events "had an allergic reaction", "issues with speech", "issues with vision", "issues with ability to stand" and "shakes" were evaluated at the emergency room visit. Therapeutic measures were taken as a result of hypersensitivity.  The lot number for bnt162b2 was not provided and will be requested during follow up.